Management of hepatitis B: 2000--summary of a workshop.

By A. Lok, E. Heathcote, J. Hoofnagle. Gastroenterology, 2001

806 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Chronic hepatitis B: Update 2009 (2009, background): “Aliment Pharmacol Ther 2004;19(3):323-329.”
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. (2006, methodology): “On reiewing these studies, there are noteworthy inferences hat can be made: (1) the use of a systematic ultrasound coring system based on the structural appearance of the iver surface, liver parenchyma, intrahepatic blood vesels, and the spleen, as was performed in our study, f Risk Factors Associat”
Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance (2018, background): “At the 2006 National Institutes of Health HBV Meeting, it was also proposed that patients with protracted, severe, acute hepatitis B (increase in international normalized ratio and deep jaundice persisting for >4 weeks) be treated.((219)) Entecavir, TAF, or TDF are preferred antivirals in this setti”
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update (2015, background): “Differentiation between these two categories of patients has been based on a HBV DNA cutoff of 2000 IU/ml [56, 57].”